Tipifarnib and naxitamab for relapsed or refractory neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 21 or younger when first diagnosed with neuroblastoma.
- You are now older than 1 year.
- Your neuroblastoma has come back after treatment or has not responded well to standard therapy.
- You have measurable disease (a tumor that can be seen on scans or bone marrow tests).
- You have recovered from the side effects of any prior cancer treatments.
- You have adequate organ function (kidney, liver, heart, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.